The European Platform for Neurodegenerative Diseases (EPND)

• DOI: 10.1002/alz.079164
• Publication Date: 2023-12-25T11:14:02Z
• Authors: Pieter Jelle Visser; Anthony J. Brookes; Phil Scordis; Niranjan Bose
• Keywords: Data Sharing; Leverage (statistics)

Abstract Background Biomarker discovery, development, and validation are reliant on large‐scale analyses of high‐quality samples data. However, access, sharing data hindered both by silos that limit collaboration, complex requirements for secure, legal, ethical sharing. The European Platform Neurodegenerative Diseases (EPND) project aims to address these challenges accelerate biomarker development validation, building a scalable, sustainable platform sample In this presentation we will give an overview the design EPND achievements in first year 5‐year project. Method is multidisciplinary consortium 29 public private partners with expertise ethical, legal regulatory aspects sharing, studies, stakeholder engagement sustainability. leverage existing research infrastructures, including Alzheimer’s Disease Data Initiative (ADDI) AD Workbench, which allow connect global network. was launched November 2021 funded Innovative Medicines (IMI, grant agreement number 101034344, epnd.org). Result project, has been finalised. its Cohort Catalogue, features information participants, from 60+ neurodegeneration cohorts, spanning 17 countries 13 disease areas, involving over 155,000 patients. addition standardised operational procedures selection, biobanking, harmonisation, have also developed white paper Finally, performed case studies ATN biomarkers plasma blood 350 patients disease, Parkinson’s Lewy body dementia. Conclusion We initiated goal collaborative into discovery biomarkers, support diagnostics disease‐modifying therapies other neurodegenerative diseases.